Integrated Biopharma Valuation
| INBPDelisted Stock | USD 0.33 0.00 0.00% |
Integrated Biopharma seems to be overvalued based on Macroaxis valuation methodology. Our model calculates the value of Integrated Biopharma from evaluating the firm fundamentals such as Return On Asset of 0.0336, current valuation of 12.05 M, and Return On Equity of 0.13 as well as inspecting its technical indicators and probability of bankruptcy. . In general, most investors encourage buying undervalued assets and selling overvalued assets since, at some point, asset prices and their ongoing real values will come together.
Overvalued
Today
Please note that Integrated Biopharma's price fluctuation is very steady at this time. Calculation of the real value of Integrated Biopharma is based on 3 months time horizon. Increasing Integrated Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Integrated otc stock is determined by what a typical buyer is willing to pay for full or partial control of Integrated Biopharma. Since Integrated Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Integrated OTC Stock. However, Integrated Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.33 | Real 0.29 | Hype 0.33 | Naive 0.33 |
The intrinsic value of Integrated Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Integrated Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Integrated Biopharma helps investors to forecast how Integrated otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Integrated Biopharma more accurately as focusing exclusively on Integrated Biopharma's fundamentals will not take into account other important factors: Integrated Biopharma Total Value Analysis
Integrated Biopharma is currently forecasted to have valuation of 12.05 M with market capitalization of 11.2 M, debt of 53 K, and cash on hands of 343 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Integrated Biopharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
12.05 M | 11.2 M | 53 K | 343 K |
Integrated Biopharma Investor Information
About 69.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.56. Some equities with similar Price to Book (P/B) outperform the market in the long run. Integrated Biopharma had not issued any dividends in recent years. Based on the key measurements obtained from Integrated Biopharma's financial statements, Integrated Biopharma is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Integrated Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Integrated Biopharma has an asset utilization ratio of 222.76 percent. This connotes that the OTC Stock is making $2.23 for each dollar of assets. An increasing asset utilization means that Integrated Biopharma is more efficient with each dollar of assets it utilizes for everyday operations.Integrated Biopharma Ownership Allocation
Integrated Biopharma has a total of 29.95 Million outstanding shares. Integrated Biopharma retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 68.58 (percent) of Integrated Biopharma outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Integrated Biopharma Profitability Analysis
The company reported the previous year's revenue of 56.25 M. Net Income was 3.84 M with profit before overhead, payroll, taxes, and interest of 6.55 M.About Integrated Biopharma Valuation
The otc valuation mechanism determines Integrated Biopharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Integrated Biopharma based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Integrated Biopharma. We calculate exposure to Integrated Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Integrated Biopharma's related companies.Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. Integrated Biopharma operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 147 people.
8 Steps to conduct Integrated Biopharma's Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Integrated Biopharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Integrated Biopharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Integrated Biopharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Integrated Biopharma's revenue streams: Identify Integrated Biopharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Integrated Biopharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Integrated Biopharma's growth potential: Evaluate Integrated Biopharma's management, business model, and growth potential.
- Determine Integrated Biopharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Integrated Biopharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Integrated Biopharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Integrated Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 29.9 M | |
| Quarterly Earnings Growth Y O Y | -0.636 | |
| Retained Earnings | -32.3 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Integrated OTC Stock
If you are still planning to invest in Integrated Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Integrated Biopharma's history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |